Form 8-K - Current report:
SEC Accession No. 0001558370-25-011145
Filing Date
2025-08-12
Accepted
2025-08-12 07:10:10
Documents
15
Period of Report
2025-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20250812x8k.htm   iXBRL 8-K 43509
2 EX-99.1 alt-20250812xex99d1.htm EX-99.1 181961
3 GRAPHIC alt-20250812xex99d1002.jpg GRAPHIC 7092
  Complete submission text file 0001558370-25-011145.txt   381347

Data Files

Seq Description Document Type Size
4 EX-101.SCH alt-20250812.xsd EX-101.SCH 3269
5 EX-101.LAB alt-20250812_lab.xml EX-101.LAB 18714
6 EX-101.PRE alt-20250812_pre.xml EX-101.PRE 12847
17 EXTRACTED XBRL INSTANCE DOCUMENT alt-20250812x8k_htm.xml XML 4868
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 251204002
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)